Pinealon
Research OnlyA synthetic tripeptide (Glu-Asp-Arg) developed by Russian researcher Vladimir Khavinson as a 'peptide bioregulator' claimed to support brain function. Part of a larger Russian research program on short peptides. Evidence comes almost exclusively from Russian publications with no independent Western replication. Not approved by any Western regulatory agency.
EDR · Glu-Asp-Arg · Pinealon peptide · T-33 peptide
Mostly preclinical · 2 human studies
- Preclinical
- 87%
- Clinical
- 13%
Based on 15 cited sources
Demonstrated effect magnitude — not a recommendation or safety claim.
Research Depth 29 (1A 12 documented clinical observation only — two small uncontrolled Russian human reports, no RCT; 1B 4 high risk of bias; 1C 2 human N<50; 1D 6 partially direct; 1E 5 modest multi-model preclinical program — in-vitro ROS in cerebellar granule/PC12/neutrophils 21978084, rat hyperhomocysteinemia 22567179, 5xFAD mouse 34071923, all single group). Mechanism 39 (2A 10 target inferred — DNA/gene-binding is computational only 33396470/22117547, no measured affinity or knockout; 2B 12 proximal ERK1/2 + SOD2/GPX1 partially mapped; 2C 9 dose-dependent ROS in cell models 21978084; 2D 8 confirmed in in-vivo rat/mouse). Plausibility 58 (3A 18 mechanism→surrogate established but human-translation links unproven; 3B 19 antioxidant/neuroprotective arm coheres with disease biology; 3C 13 same-class Khavinson tripeptides KED/epithalon show analogous effects; 3D 8 moderately broad multi-system claim via gene-regulation theory). Global Coverage 19 (4A 5 single Khavinson/St. Petersburg group; 4B 6 one country; 4C 8 ~15 narrow-scope studies; 4D 0 no governance review). Community Experience 41 (5A 9 niche enthusiast discussion; 5B 15 multi-year track record; 5C 7 sparse/mixed reports; 5D 10 no recurring adverse signal over small exposure — not a safety claim). Effectiveness not established: no quantified human efficacy estimate and no meaningful community effect signal (empty positive/negative report sets).
The proposed mechanisms of Pinealon are based almost exclusively on Russian preclinical studies. No independent Western replication exists, and human mechanistic data is lacking.
How It Works (Simplified)
Pinealon is claimed to act through several pathways, though these remain largely unvalidated:
Claimed to suppress reactive oxygen species (ROS) and upregulate antioxidant enzymes like SOD and glutathione peroxidase in neuronal cells.
Proposed to delay ERK1/2 activation under oxidative stress, potentially protecting neurons from excitotoxicity-induced damage.
Khavinson theory claims DNA binding and gene expression modulation. This extraordinary claim lacks rigorous independent validation.
Claimed to reduce neuronal apoptosis and preserve dendritic spine density, though evidence is limited to single-laboratory Russian studies.
Key Research: Khavinson V et al. (Russia, 2011) demonstrated ROS suppression in cerebellar granule cells. PMID:21978084
Important Limitations
- Nearly all studies from single research group (Khavinson laboratory, St. Petersburg)
- No independent Western replication of any findings
- DNA binding mechanism is extraordinary and unvalidated
- Translation to human physiology is completely unconfirmed
- Pharmacokinetics in humans not characterized
- Oral bioavailability likely very low (typical for peptides)
- Products are unregulated research chemicals with uncertain purity
Based on limited preclinical data: Proposed antioxidant effects may begin. Russian cell studies show ROS suppression within hours to days of exposure. No human timeline data available. Oral bioavailability likely very low for this tripeptide.
PMID:21978084Animal studies suggest ongoing neuroprotective signaling. ERK1/2 modulation observed in cell models within this timeframe. Translation to human effects is completely speculative and unvalidated.
PMID:21978084Mouse studies showed dendritic spine density changes over several weeks. Long-term effects, optimal duration, and human pharmacokinetics are unknown. All timeline estimates are extrapolated from Russian preclinical data.
PMID:34071923No long-term human data exists. Russian bioregulator theory suggests extended use for 'cellular regulation' but this lacks scientific validation. Safety of prolonged use is uncharacterized.
Research-based observations
This timeline reflects observations from published clinical and preclinical studies. Individual responses may vary significantly. This is not a guarantee of effects or a dosing schedule. Consult qualified healthcare providers for personalized guidance.
Good Signs (6 indicators)
Warning Signs (5 indicators)
Bad Signs (7 indicators)
For Research Evaluation Only
These quality indicators are general guidelines based on typical peptide characteristics. Professional laboratory testing (HPLC, mass spectrometry) provides definitive quality verification. This checklist is for initial visual evaluation only.
Epithalon
CompatibleBoth are Khavinson bioregulator peptides with different proposed targets. Epithalon focuses on telomerase activation while Pinealon targets brain function. No interaction studies available; both lack independent validation.
Semax
CompatibleDifferent mechanisms of action (Semax is ACTH-derived with BDNF modulation vs Pinealon's proposed antioxidant effects). Both target cognitive function through distinct pathways. No combined studies exist.
Cortexin
CompatibleBoth are Russian neuropeptide preparations. Cortexin is a complex polypeptide mixture while Pinealon is a defined tripeptide. Theoretical complementary effects; no interaction data available.
Selank
CompatibleNon-overlapping mechanisms. Selank modulates GABA and serotonin systems while Pinealon claims antioxidant and ERK modulation. No contraindications known; both lack rigorous human data.
BPC-157
CompatibleDifferent primary targets (Pinealon for brain, BPC-157 for tissue repair). No known interactions; both peptides lack comprehensive human pharmacokinetic data.
Dihexa
CautionBoth claimed to have cognitive effects. Dihexa has potent HGF receptor activity. Combining experimental nootropic peptides with unknown safety profiles warrants caution.
Research Note: Interaction data is based on published literature, mechanistic understanding, and theoretical considerations. Most peptide combinations lack direct clinical study. This information is for educational purposes only and does not constitute medical advice. Always consult qualified healthcare providers.
Key Studies Cited
Full reference list available on request. All citations link to PubMed for verification.
This dossier synthesizes available evidence from peer-reviewed literature, regulatory documents, and clinical trial registries. Evidence strength ratings follow a modified GRADE approach.
For complete methodology details, see our Methodology page.
Important Disclaimer
This dossier is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making health decisions.
Get Research Alerts
New dossiers and major study summaries delivered to your inbox. Evidence-graded, citation-backed research you can trust.
No spam. Unsubscribe anytime.
Compare Pinealon
Related Peptides
Alixorexton
ALKS 2680 · ALKS-2680
An oral orexin receptor 2 (OX2R) agonist developed by Alkermes for narcolepsy type 1 (NT1). Phase 2 clinical trials demonstrated improvements in excessive daytime sleepiness and cataplexy with once-daily dosing. Represents a novel approach to restore orexin signaling in patients who have lost orexin-producing neurons.
Cerebrolysin
FPF-1070 · N-PEP-12 · Renacenz
Cerebrolysin is a porcine brain-derived peptide mixture approved in 50+ countries for stroke, dementia, and traumatic brain injury. It is NOT FDA-approved in the United States despite decades of international clinical use. Contains neurotrophic peptide fragments mimicking BDNF, GDNF, NGF, and CNTF. Mixed Phase 3 results but positive meta-analyses and widespread adoption in Europe, Asia, and Latin America.
Cerluten
Brain cytamin · Cerebral peptides · A-5 brain peptides
A cytamin-class peptide supplement derived from brain tissue, part of the Russian bioregulator framework. Marketed as an oral supplement for cognitive support and neuroprotection. Contains peptide complexes rather than defined sequences. No Western clinical validation.
Dihexa
PNB-0408 · N-hexanoic-Tyr-Ile-(6) aminohexanoic amide
An angiotensin IV analog developed by Washington State University researchers, claimed to enhance cognition through HGF/c-Met signaling. Gained attention for extreme potency claims (10 million times more potent than BDNF), but evidence is limited to rodent studies from a single research group with no human clinical trials. Sold as a research chemical with unknown safety profile.
DSIP
Delta Sleep Inducing Peptide · Delta Sleep-Inducing Peptide · WAGGDASGE
A nonapeptide discovered in 1977 that was initially thought to induce delta wave sleep. Research has shown broader neuromodulatory effects including stress-protection and analgesia, though its role as an endogenous sleep factor remains controversial.
N-Acetyl Selank Amidate
NA-Selank · N-Acetyl Selank · Acetyl-Selank-Amidate +1
A modified version of Selank with N-terminal acetylation and C-terminal amidation designed to enhance stability and bioavailability. While the parent compound Selank is approved in Russia, N-Acetyl Selank Amidate has no independent clinical research and relies entirely on extrapolated claims from Selank studies.